Related Experiment Video
Updated: May 10, 2026

An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
Published on: May 8, 2020
[Immunization for the immunosuppressed traveler].
Gilles Eperon1, Bernard Vaudaux
1Service de médecine internationale et humanitaire, Département de médecine, communautaire, de premier recours et des urgences, HUG, 1211 Genève 14. gilles.eperon@hcuge.ch
Vaccinating immunosuppressed patients for travel requires balancing infection risk and vaccine effectiveness. Assessing immunological memory or antibody levels helps determine protection for immunocompromised individuals.
Area of Science:
- Immunology
- Infectious Diseases
- Travel Medicine
Background:
- Increased international travel and immunosuppressive therapies lead to more immunocompromised patients seeking pre-travel medical advice.
- Vaccinating immunocompromised individuals presents unique challenges, requiring careful consideration of both disease risks and vaccine efficacy.
- Understanding immune responses is crucial, as effectiveness often relies on immunological memory or measurable antibody levels.
Observation:
- Immunosuppressed patients face heightened risks of infectious diseases when traveling internationally.
- The decision to vaccinate these patients involves a complex risk-benefit analysis.
- Evaluating existing immunological memory or determining antibody titers can inform protective potential.
Findings:
- Vaccine effectiveness in immunosuppressed individuals is often linked to pre-existing immunological memory.
- Antibody level testing can be a valuable tool for assessing protection in this population.
- Clinical case studies highlight practical difficulties encountered by general practitioners.
Implications:
- Tailored vaccination strategies are essential for immunocompromised travelers.
- Further research into optimizing vaccine responses in immunosuppressed populations is warranted.
- Improved clinical guidelines are needed to support healthcare providers in managing travel health for vulnerable patients.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
Related Concept Videos
Vaccinations
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cell-mediated Immune Responses
Hypersensitivity Reactions: Immune-Complex Reactions